Andrew Grimm

Andrew Grimm has an extensive work experience in the medical field. Andrew is currently the Vice President of Global Clinical Development for Metabolic Diseases at Ultragenyx, a position they have held since March 2023. Prior to this role, they served as the Executive Medical Director at Ultragenyx from June 2020 to April 2023. Before joining Ultragenyx, Andrew worked as a Medical Director at Takeda from January 2019 to June 2020. Andrew also served as an Assistant Professor at UMass Memorial Medical Center from 2016 to 2020. Prior to that, they held the position of Medical Director at Shire from August 2015 to January 2019. Andrew's earlier experience includes roles as an Assistant Professor at UCSF and a Pediatric Gastroenterology Fellow at UCSF Benioff Children's Hospital. Andrew began their career as a Pediatric Resident at St. Louis Children's Hospital and Boston Children's Hospital.

Andrew Grimm completed their education in a chronological manner. Andrew started by earning their Bachelor of Science (SB) degree in Biology from the Massachusetts Institute of Technology in 2000. In the same year, they also received a Doctor of Medicine (MD) degree from the Washington University School of Medicine in St. Louis, specializing in the field of Medicine. Concurrently, they obtained a Doctor of Philosophy (PhD) in Molecular Genetics from Washington University in St. Louis. In 1997, they had earlier attended the University of Minnesota. Additionally, in 2000, they briefly studied Ethics and Health Policy at the University of Bergen (UiB).